Mechanism relevant to hepatocellular carcinoma occurrence after negative conversion of viral DNA in treatment of chronic hepatitis B patients with nucleos(t)ide drugs
10.3760/cma.j.issn.1007-3418.2019.11.017
- VernacularTitle: 核苷（酸）类药物治疗慢性乙型肝炎患者病毒DNA阴转后发生肝细胞癌的相关机制
- Author:
Tianjing GAO
1
;
Gengyu HAN
2
;
Fengmin LU
3
Author Information
1. Peking University First Hospital, Beijing 100032, China
2. Peking University Third Hospital, Beijing 100191, China
3. Department of Microbiology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China
- Publication Type:Review
- Keywords:
Hepatitis B virus;
Carcinoma, hepatocellular;
Nucleoside analogs;
Gene integration;
Inflammatory damage
- From:
Chinese Journal of Hepatology
2019;27(11):905-909
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma (HCC) is a common malignant tumor in China, and most of the patients have a background of chronic HBV infection. Nucleos(t)ide drugs (NAs) are currently recommended by major guidelines as a first-line treatments for chronic hepatitis B. However, it is still clinically possible to observe that some patients who have acquired virological response (HBV DNA below the lower detection limit) after NAS treatment progress to HCC, and its mechanism of development is still unclear. In this review, the mechanism relevant to HCC progression in treatment of chronic hepatitis B patients with NAs is analyzed mainly from the aspects of gene integration and persistent inflammatory injury.
